SYMPHONY EVOLUTION, INC.
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- -
Clinical Trials
10
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Maintenance Study on the Long Term Safety of XL999
- Conditions
- Advanced Malignancies
- First Posted Date
- 2009-08-07
- Last Posted Date
- 2010-09-24
- Lead Sponsor
- Symphony Evolution, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT00955084
- Locations
- 🇺🇸
Hematology Oncology Associates of Rockland Union State Bank Cancer Center, Nyack, New York, United States
🇺🇸University of Texas Cancer Center, San Antonio, Texas, United States
Safety Study of XL999 in Adults With Non-Small-Cell Lung Cancer
- Conditions
- Non-Small-Cell Lung Cancer
- First Posted Date
- 2007-06-26
- Last Posted Date
- 2010-02-19
- Lead Sponsor
- Symphony Evolution, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT00491699
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸Peachtree Hematology Oncology Consultants, Atlanta, Georgia, United States
🇺🇸Wayne State University, Karmanos Cancer Institute, Detroit, Michigan, United States
Study of XL999 in Patients With Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid LeukemiaAML
- First Posted Date
- 2006-05-08
- Last Posted Date
- 2010-02-22
- Lead Sponsor
- Symphony Evolution, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT00322673
- Locations
- 🇺🇸
Eddie Hu, Alhambra, California, United States
🇺🇸Ronald Paquette, Los Angeles, California, United States
🇺🇸The Thomas and Dorothy Leavey Cancer Center, Northridge, California, United States
Study of XL784 in Patients With Albuminuria Due to Diabetic Nephropathy
- First Posted Date
- 2006-04-11
- Last Posted Date
- 2010-02-23
- Lead Sponsor
- Symphony Evolution, Inc.
- Target Recruit Count
- 125
- Registration Number
- NCT00312780
- Locations
- 🇺🇸
Parkway Medical Center, Birmingham, Alabama, United States
🇺🇸Winston Technology, Inc., Haleyville, Alabama, United States
🇺🇸Redpoint Research, Phoenix, Arizona, United States
Study of XL999 in Patients With Multiple Myeloma
- Conditions
- Multiple Myeloma
- First Posted Date
- 2006-03-20
- Last Posted Date
- 2010-02-22
- Lead Sponsor
- Symphony Evolution, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT00304590
- Locations
- 🇺🇸
UCLA Oncology-Hematology Associates, Ltd., Los Angeles, California, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Joliet Oncology-Hematology Associates, Ltd., Joliet, Illinois, United States
- Prev
- 1
- 2
- Next